{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:23:35Z","timestamp":1768973015126,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Fundacao para a Ciencia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jconrel.2024.01.065","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T11:16:31Z","timestamp":1706958991000},"page":"540-556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy"],"prefix":"10.1016","volume":"367","author":[{"given":"Rui","family":"Freitas","sequence":"first","affiliation":[]},{"given":"Andreia","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Dylan","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Relvas-Santos","sequence":"additional","affiliation":[]},{"given":"Fl\u00e1via","family":"Castro","sequence":"additional","affiliation":[]},{"given":"Eduardo","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Cristiana","family":"Gaiteiro","sequence":"additional","affiliation":[]},{"given":"Janine","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Cotton","sequence":"additional","affiliation":[]},{"given":"Martina","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Eiras","sequence":"additional","affiliation":[]},{"given":"Beatriz","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Palmeira","sequence":"additional","affiliation":[]},{"given":"Margareta P.","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]},{"given":"Andreia","family":"Peixoto","sequence":"additional","affiliation":[]},{"given":"L\u00facio Lara","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9 M.N.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Alexandre","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jconrel.2024.01.065_bb0005","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41578-019-0108-1","article-title":"Cancer nanomedicine for combination cancer immunotherapy","volume":"4","author":"Nam","year":"2019","journal-title":"Nat. Rev. Mater."},{"issue":"7","key":"10.1016\/j.jconrel.2024.01.065_bb0010","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.065_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2024.01.065_bb0020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"issue":"7463","key":"10.1016\/j.jconrel.2024.01.065_bb0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.065_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gpb.2021.03.005","article-title":"Glycoproteogenomics: setting the course for next-generation Cancer Neoantigen discovery for Cancer vaccines","volume":"19","author":"Ferreira","year":"2021","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"8","key":"10.1016\/j.jconrel.2024.01.065_bb0035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/1878-0261.12035","article-title":"Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours","volume":"11","author":"Cotton","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jconrel.2024.01.065_bb0040","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fonc.2019.00380","article-title":"Protein glycosylation and tumor microenvironment alterations driving Cancer hallmarks","volume":"9","author":"Peixoto","year":"2019","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2024.01.065_bb0045","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer\u202f: mechanisms and clinical implications","volume":"16","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.jconrel.2024.01.065_bb0050","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.7150\/thno.67409","article-title":"Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion","volume":"12","author":"Gaiteiro","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.065_bb0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13046-021-01988-6","article-title":"Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer","volume":"40","author":"Peixoto","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.jconrel.2024.01.065_bb0060","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/ijc.25778","article-title":"Seromic profiling of colorectal cancer patients with novel glycopeptide microarray","volume":"128","author":"Pedersen","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2024.01.065_bb0065","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/bcr2841","article-title":"Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis","volume":"13","author":"Blixt","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"25","key":"10.1016\/j.jconrel.2024.01.065_bb0070","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1073\/pnas.2432220100","article-title":"A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor","volume":"100","author":"Apostolopoulos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.065_bb0075","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2249.2005.02965.x","article-title":"O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma","volume":"143","author":"Stepensky","year":"2006","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2024.01.065_bb0080","first-page":"236","article-title":"Cancer vaccine THERATOPE- Biomira","volume":"4","author":"Adis International, L","year":"2003","journal-title":"Drugs R D"},{"issue":"4","key":"10.1016\/j.jconrel.2024.01.065_bb0085","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/biom2040435","article-title":"Sialyl-Tn in cancer: (how) did we miss the target?","volume":"2","author":"Julien","year":"2012","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.jconrel.2024.01.065_bb0090","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/glycob\/cwj044","article-title":"Chemoenzymatically synthesized multimeric Tn\/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance","volume":"16","author":"Sorensen","year":"2006","journal-title":"Glycobiology"},{"issue":"41","key":"10.1016\/j.jconrel.2024.01.065_bb0095","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/anie.200902564","article-title":"A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response","volume":"48","author":"Kaiser","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"20","key":"10.1016\/j.jconrel.2024.01.065_bb0100","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1039\/D0NJ06021F","article-title":"Single-pot enzymatic synthesis of cancer-associated MUC16 O-glycopeptide libraries and multivalent protein glycoconjugates: a step towards cancer glycovaccines","volume":"45","author":"Freitas","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.jconrel.2024.01.065_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108144","article-title":"Immunomodulatory glycomedicine: introducing next generation cancer glycovaccines","volume":"65","author":"Freitas","year":"2023","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jconrel.2024.01.065_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12014-018-9198-9","article-title":"CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications","volume":"15","author":"Azevedo","year":"2018","journal-title":"Clin. Proteomics"},{"issue":"13","key":"10.1016\/j.jconrel.2024.01.065_bb0115","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/1873-3468.13432","article-title":"O-glycan truncation enhances cancer-related functions of CD44 in gastric cancer","volume":"593","author":"Mereiter","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2024.01.065_bb0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.actbio.2017.09.016","article-title":"Pro-inflammatory chitosan\/poly(gamma-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity","volume":"63","author":"Castro","year":"2017","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.jconrel.2024.01.065_bb0125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/glycob\/cwaa067","article-title":"ISOGlyP: de novo prediction of isoform-specific mucin-type O-glycosylation","volume":"31","author":"Mohl","year":"2021","journal-title":"Glycobiology"},{"issue":"10","key":"10.1016\/j.jconrel.2024.01.065_bb0130","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/emboj.2013.79","article-title":"Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology","volume":"32","author":"Steentoft","year":"2013","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.065_bb0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10495-006-0488-8","article-title":"Engagement of CD44 up-regulates Fas ligand expression on T cells leading to activation-induced cell death","volume":"12","author":"Nakano","year":"2007","journal-title":"Apoptosis"},{"key":"10.1016\/j.jconrel.2024.01.065_bb0140","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3389\/fonc.2020.01622","article-title":"Tn antigen expression contributes to an immune suppressive microenvironment and drives tumor growth in colorectal Cancer","volume":"10","author":"Cornelissen","year":"2020","journal-title":"Front. Oncol."},{"issue":"29","key":"10.1016\/j.jconrel.2024.01.065_bb0145","doi-asserted-by":"crossref","first-page":"18985","DOI":"10.1039\/D2RA03286D","article-title":"Precise immunological evaluation rationalizes the design of a self-adjuvanting vaccine composed of glycan antigen, TLR1\/2 ligand, and T-helper cell epitope","volume":"12","author":"Chang","year":"2022","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.065_bb0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/acs.bioconjchem.8b00661","article-title":"Effects of conformational changes in peptide-CRM(197) conjugate vaccines","volume":"30","author":"Jaffe","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"17","key":"10.1016\/j.jconrel.2024.01.065_bb0155","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1158\/0008-5472.CAN-07-1035","article-title":"Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells","volume":"67","author":"Napoletano","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.jconrel.2024.01.065_bb0160","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bcp.12422","article-title":"Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies","volume":"78","author":"Swaminathan","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.01.065_bb0165","series-title":"The Biomaterials: Silver Jubilee Compendium","first-page":"219","article-title":"Review: Biomaterial-associated thrombosis: Roles of coagulation factors, complement, platelets and leukocytes","author":"Gorbet","year":"2004"},{"key":"10.1016\/j.jconrel.2024.01.065_bb0170","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.colsurfa.2012.09.024","article-title":"The electrokinetic potential of therapeutic proteins and its modulation: impact on protein stability","volume":"415","author":"Wagner","year":"2012","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.jconrel.2024.01.065_bb0175","series-title":"Bioconjugate Techniques (Third Edition)","first-page":"839","article-title":"Chapter 19 - vaccines and immunogen conjugates","author":"Hermanson","year":"2013"},{"issue":"5","key":"10.1016\/j.jconrel.2024.01.065_bb0180","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"9\u201310","key":"10.1016\/j.jconrel.2024.01.065_bb0185","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/smll.201201390","article-title":"Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking","volume":"9","author":"Duan","year":"2013","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2024.01.065_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175632","article-title":"Adjuvants approved for human use: what do we know and what do we need to know for designing good adjuvants?","volume":"945","author":"Reyes","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.065_bb0195","doi-asserted-by":"crossref","first-page":"19065","DOI":"10.1038\/s41598-019-55281-w","article-title":"A reporter mouse for non-invasive detection of toll-like receptor ligands induced acute phase responses","volume":"9","author":"Huang","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.jconrel.2024.01.065_bb0200","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/icb.2016.65","article-title":"IgG subclass co-expression brings harmony to the quartet model of murine IgG function","volume":"94","author":"Collins","year":"2016","journal-title":"Immunol. Cell Biol."},{"issue":"48","key":"10.1016\/j.jconrel.2024.01.065_bb0205","doi-asserted-by":"crossref","first-page":"15998","DOI":"10.1039\/D1SC05736G","article-title":"Fully synthetic Mincle-dependent self-adjuvanting cancer vaccines elicit robust humoral and T cell-dependent immune responses and protect mice from tumor development","volume":"12","author":"Luo","year":"2021","journal-title":"Chem. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2024.01.065_bb0210","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1021\/jacs.8b13503","article-title":"Structure-based Design of Potent Tumor-Associated Antigens: modulation of peptide presentation by single-atom O\/S or O\/se substitutions at the Glycosidic linkage","volume":"141","author":"Companon","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.jconrel.2024.01.065_bb0215","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and Cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.01.065_bb0220","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/med.21493","article-title":"Carbohydrate-based vaccines for oncotherapy","volume":"38","author":"Wei","year":"2018","journal-title":"Med. Res. Rev."},{"issue":"48","key":"10.1016\/j.jconrel.2024.01.065_bb0225","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.1039\/C6CC02000C","article-title":"Multi-component self-assembled anti-tumor nano-vaccines based on MUC1 glycopeptides","volume":"52","author":"Sun","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2024.01.065_bb0230","article-title":"Neoantigen: a new breakthrough in tumor immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2024.01.065_bb0235","doi-asserted-by":"crossref","first-page":"675 e1","DOI":"10.1016\/j.urolonc.2017.08.012","article-title":"Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases","volume":"35","author":"Lima","year":"2017","journal-title":"Urol. Oncol."},{"issue":"3\u20134","key":"10.1016\/j.jconrel.2024.01.065_bb0240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1101\/gad.319889.118","article-title":"CD44 splice isoform switching determines breast cancer stem cell state","volume":"33","author":"Zhang","year":"2019","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.jconrel.2024.01.065_bb0245","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/liv.13687","article-title":"MiR-492 regulates metastatic properties of hepatoblastoma via CD44","volume":"38","author":"von Frowein","year":"2018","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.jconrel.2024.01.065_bb0250","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/sj.bjc.6605762","article-title":"Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer","volume":"103","author":"Lugli","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2024.01.065_bb0255","first-page":"6724","article-title":"Expression of CD44 in pancreatic cancer and its significance","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.01.065_bb0260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13046-022-02335-z","article-title":"A roadmap for translational cancer glycoimmunology at single cell resolution","volume":"41","author":"Peixoto","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.jconrel.2024.01.065_bb0265","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41565-019-0512-0","article-title":"Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators","volume":"14","author":"Conniot","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.01.065_bb0270","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jconrel.2024.01.065_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041664","article-title":"Target score-a proteomics data selection tool applied to esophageal Cancer identifies GLUT1-Sialyl Tn Glycoforms as biomarkers of Cancer aggressiveness","volume":"22","author":"Cotton","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924000804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:56:05Z","timestamp":1759164965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924000804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":55,"alternative-id":["S0168365924000804"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.065","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}